#biotechnology

#biotechnology

Young researchers are innovating in cancer drug development, focusing on pioneering techniques like cancer reversion to reduce the need for traditional treatments.

Pliant Therapeutics is cutting 45% of its workforce to extend cash runway after halting a major trial due to safety issues.

Unity Biotechnology lays off all employees to reduce financial losses.

Anthropic is launching an AI for Science program to support high-impact research with API credits for selected researchers.

AI can design novel enzymes that perform multi-step reactions effectively, revolutionizing enzyme engineering.

CRISPR Therapeutics is facing significant challenges with declining stock performance and heightened short interest.

Billionaires Julian and Felix Baker significantly influence biotech investments through their hedge fund, Baker Bros. Advisors.

The complex ecosystem of U.S. cancer research is threatened by funding instability and political shifts.

Significant funding rounds highlight emerging biotech and tech companies, showcasing innovation in addressing critical needs across multiple sectors.

Avidicure launched with $50M funding to develop multifunctional antibodies for cancer treatment, aiming to revolutionize oncology with innovative therapies.

Augustine Therapeutics raises €77.7M for CMT disease treatment, marking a significant step in innovative therapeutics for neurodegenerative conditions.

Lab-grown leather from T. rex DNA represents a breakthrough in sustainable luxury fashion.

The project aims to create luxury leather from lab-grown T-Rex skin, but faces skepticism regarding feasibility and available genetic material.

Tim Friede's self-experimentation offers a groundbreaking approach to developing a universal antivenom for snake bites.

Tim Friede's unique exposure to snake venom has led to the development of an antivenom for 19 snake species, showcasing new possibilities in snakebite treatment.

Pet owners prioritize their pets' health, with many willing to incur debt for their care.

A company named Loyal is developing drugs aimed at extending dogs' healthy lifespan.

A groundbreaking discovery reveals that a complex single-celled alga can convert nitrogen, potentially revolutionizing agriculture and reducing reliance on synthetic fertilizers.

Breakthrough in lab-grown meat achieved with bioreactor technology that mimics blood vessels, supporting larger chunks of chicken meat.

This innovation could revolutionize lab-grown meat production and organ growth.

T.Rex leather is a new sustainable luxury material engineered from fossil DNA.

This innovative material combines genomic engineering and advanced tissue engineering.

23andMe's decline from a $6 billion valuation culminated in Chapter 11 bankruptcy amid unsuccessful business ventures and market challenges.

CEO Anne Wojcicki resigned but expressed continued belief in the company's potential.

OpenSNP will shut down due to risks of genetic data misuse, especially following 23andMe's bankruptcy.

23andMe's DNA data from 15 million individuals is being auctioned, raising concerns about privacy versus potential scientific benefits.

Latent Labs aims to revolutionize protein design and drug discovery using AI technology developed by former DeepMind scientist Simon Kohl.

Latent Labs is advancing AI to revolutionize protein design for biotech and pharmaceutical applications.